Esperanza - Treatment Program for Multiple Sclerosis, Post Stroke and Lyme Positive Motor Neurone/ALS Disease

	Esperanza NeuroPeptides ®
	\| HOME \| ONLINE SHOP \| Q & A \| TECHNOLOGIES \| NEWS \| PROFILE \| \| RECENT ARTICLES \| TESTIMONIALS \| EXECUTIVE SUMMARY \| CONTACT US \| LEGAL \|

MSN EMAIL NEWSLETTER

ESPERANZA SHOP

SUBSCRIBE TO MSN NEWS

POWERPOINT PRESENTATION

Click here for my testimonial

multiple sclerosis ('məl-tə-pəl scle-ro-sis) (MS) - the demyelination process occurring in patches throughout the white matter of the central nervous system, sometimes extending into the gray matter; symptoms of lesions of the white matter can be weakness, incoordination, paresthesias, speech disturbances, fatigue, pain, ataxia,and visual complaints

TREATMENT PROGRAM

Treatment Overview and Clinic Protocols

Multiple Sclerosis (MS)

How The Esperanza Homeopathic NeuroPeptide Works After Dosing For Multiple Sclerosis (MS)

Dosing Procedures And Protocols For Multiple Sclerosis (MS)

Esperanza NeuroPeptide Do's & Dont's

Overview of Esperanza NeuroPeptide Treatment Pricing

Ataxias & Olivopontocerebeller Atrophy (OPCA)

Post Stroke (PS)

Primary Lateral Sclerosis (PLS)

Motor Neuron Disease/Amyotrophic Lateral Sclerosis

Lyme Disease (LYME)

Treatment Overview and Clinic Protocols for Multiple Sclerosis (MS), Ataxias & Olivopontocerebeller Atrophy (OPCA), Post Stroke (PS), Motor Neuron Disease/Amyotrophic Lateral Sclerosis (MND/ALS), Primary Lateral Sclerosis (PLS), or other diseases/ailments.

We have clinic facilities in The United Kingdom, USA, Europe, Mexico, Israel, Australia/New Zealand and South Africa and the protocols vary for each clinic. These clinics have an initial one day 3 to 4 hour treatment with optional follow-up visits. For details on the protocols for the clinic nearest you please email us with your request for specific clinic information by clicking here.

See the various clinic locations and protocols below:

3 Of Over 100 Esperanza Clinics Worldwide

UNITED KINGDOM (UK) - Locations click here. Clinic Protocols click here.

IRELAND (EIRE) - Locations click here. Clinic Protocols click here.

UNITED STATES OF AMERICA (USA) - Locations click here. Clinic Protocols click here.

EUROPE - (EU) - Locations click here. Clinic Protocols click here.

MEXICO - Locations click here click here. Clinic Protocols click here.

SOUTH AFRICA - Locations click here click here. Clinic Protocols click here.

ISRAEL - Locations click here click here. Clinic Protocols click here.

BAHAMAS - Locations click here click here. Clinic Protocols click here.

What is the Treatment?

The treatment is a Homeopathic sublingual (under the tongue) spray called Esperanza Homeopathic NeuroPeptide, that is taken once a day. It is our unique peptide in a saline solution that allows conduction across the nerve muscle junctions, allowing the possibility of return of function. It is safe and tasteless.

What should I expect?

Every case and patient is different. In regards to Multiple Sclerosis, for example, it depends a lot on where your lesions are located and the extent of damage.

Most patients who have slurred speech notice varying degrees of improvement after going on the NeuroPeptide treatment. Imbalance is a problem for many patients, and after going on the NeuroPeptide marked improvement has been shown over time in a variety of patients. In many patients we see significant positive changes in upper body and lower body motor function (example: crossing a bad leg over he good leg). There is almost always an increase in energy and strength and a decrease in fatigue with our treatment. It is the only treatment that allows you the possibility to regain function and/or motor skills in any of the diseases/conditions noted above. However, please do not expect miracles ... remember the MS has taken it's toll on your body for years (probably well before you were even diagnosed) and any return of function and motor skills that may transpire can take varied lengths of time in different patients.

Click here to read a more definitive report on expectations and possible results after your Esperanza NeuroPeptide treatment

Is it a cure?

No this treatment is not a cure nor a guarantee of any function return, however our longest Multiple Sclerosis patient is now in his 20th year with an outstanding quality of life. If he stops the peptide, he will lose balance and motor function within 1-2 days. Post Stroke patients on the peptide do much better in rehab and are often able to go off the peptide after recovery. We are optimistic that we will see cures for Multiple Sclerosis but for now the treatment provides many patients a quality of life they never thought possible.

What to bring?

We encourage patients to bring copies of any MRI scans and copies of any and all medical records pertaining to your condition.

For information on our clinics and travel directions to clinics worldwide click here

What is the cost of the treatment?

MULTIPLE SCLEROSIS (MS) TREATMENT - Esperanza Peptide offers five treatment prices (6-month, 9-month, 12-month, 18-month and 24-month). First, we offer subsidised, 12-month, 18-month and 24-month treatments and NeuroPeptide supply, that costs the participating patients in the UK and Europe the following £6,750 (UK) for 12-months, £9,990 for 18-months and £11,880 for 24-months. In the USA, Canada and the Rest Of The World the prices are $12,500 (USA) for 12-months, $17,000 for 18-months and $24,000 for 24-month.

Second, we offer 6-month and 9-month treatment time frames for those that want to try the Esperanza NeuroPeptide treatment before fully committing to the full-year,18-month or 24-month treatment and supply. The 6-month and 9-month treatment and supply prices are without clinics, are not subsidised and are delivered to the patient via courier with full dosing instructions. The cost for these non-subsidised 6-month and 9-month treatments and supplies are £5,450 (UK) for a 9-month supply and £4,000 for a 6-month supply. In the USA, Canada and the Rest Of The World the cost for 9-month is $10,000 (USA) and 6-month is $7,500. Again, the 6-month and 9-month treatment and supply (unlike the 12-month, 18-month and 24-month treatment price) is not subsidised and does not include clinic visit and workups.

The 12-month, 18-month and 24-month costs include all of the clinical assessments, dosing analysis, and consultations with our Practitioners and clinic team, as well as one year's supply of the Esperanza Peptide Homeopathic Sublingual Spray.

Multiple Sclerosis please see What is MULTIPLE SCLEROSIS (MS)?

ATAXIAS & OLIVOPONTOCEREBELLAR ATROPHY (OPCA) TREATMENT - Esperanza Peptide offers five treatment prices (half-year, 9-month, 12-month, 18-month and 24-month). First, we offer subsidised, 12-month, 18-month and 24-month treatments and NeuroPeptide supply, that costs the participating patient in the UK and Europe the following £6,750 (UK) for 12-months, £9,990 for 18-months and £11,880 for 24-months. In the USA, Canada and the Rest Of The World the prices are $12,500 (USA) for 12-months, $17,000 for 18-months and $24,000 for 24-month.

To find out more information about Ataxias & Olivopontocerebeller Atrophy please see What is ATAXIAS & OLIVOPONTOCEREBELLAR ATROPHY TREATMENT (OPCA)?

POST STROKE (PS) TREATMENT - Esperanza Peptide offers five treatment prices (half-year, 9-month, 12-month, 18-month and 24-month). First, we offer subsidised, full year, 18-month and 24-month treatments and NeuroPeptide supply, that costs the participating patient in the UK and Europe the following £6,750 (UK) for 12-months, £9,990 for 18-months and £11,880 for 24-months. In the USA, Canada and the Rest Of The World the prices are $12,500 (USA) for 12-months, $17,000 for 18-months and $24,000 for 24-month.

To find out more information about Post Stroke please see What is POST STROKE (PS)?

PRIMARY LATERAL SCLEROSIS (PLS) TREATMENT - Esperanza Peptide offers five treatment prices (12-month, 9-month, 12-month, 18-month and 24-month). First, we offer subsidised, full year, 18-month and 24-month treatments and NeuroPeptide supply, that costs the participating patient in the UK and Europe the following £6,750 (UK) for 12-months, £9,990 for 18-months and £11,880 for 24-months. In the USA, Canada and the Rest Of The World the prices are $12,500 (USA) for 12-months, $17,000 for 18-months and $24,000 for 24-month.

To find out more information about Primary Lateral Sclerosis please see What is PRIMARY LATERAL SCLEROSIS?

MOTOR NEURON DISEASE/AMYOTROPHIC LATERAL SCLEROSIS (MND/ALS) TREATMENT - Esperanza Peptide offers five treatment prices (12-month, 9-month, 12-month, 18-month and 24-month). First, we offer subsidised, full year, 18-month and 24-month treatments and NeuroPeptide supply, that costs the participating patient in the UK and Europe the following £6,750 (UK) for 12-months, £9,990 for 18-months and £11,880 for 24-months. In the USA, Canada and the Rest Of The World the prices are $12,500 (USA) for 12-months, $17,000 for 18-months and $24,000 for 24-month.

Second, we offer 6-month and 9-month treatment time framesfor those that want to try the Esperanza NeuroPeptide treatment before fully committing to the full-year,18-month or 24-month treatment and supply. The 6-month and 9-month treatment and supply prices are without clinics, are not subsidised and are delivered to the patient via courier with full dosing instructions. The cost for these non-subsidised 6-month and 9-month treatments and supplies are £5,450 (UK) for a 9-month supply and £4,000 for a 6-month supply. In the USA, Canada and the Rest Of The World the cost for 9-month is $10,000 (USA) and 6-month is $7,500. Again, the 6-month and 9-month treatment and supply (unlike the 12-month, 18-month and 24-month treatment price) is not subsidised and does not include clinic visit and workups.

To find out more information about MND/ALS please see What is MOTOR NEURON DISEASE/AMYOTROPHIC LATERAL SCLEROSIS?

LYME DISEASE TREATMENT - LYME DISEASE TREATMENT - Esperanza Peptide offers five treatment prices (12-month, 9-month, 12-month, 18-month and 24-month). First, we offer subsidised, full year, 18-month and 24-month treatments and NeuroPeptide supply, that costs the participating patient in the UK and Europe the following £6,750 (UK) for 12-months, £9,990 for 18-months and £11,880 for 24-months. In the USA, Canada and the Rest Of The World the prices are $12,500 (USA) for 12-months, $17,000 for 18-months and $24,000 for 24-month.

To find out more information about Lyme Disease please see What is LYME DISEASE?

Please Note:

The above costs include your supply of Esperanza Homeopathic NeuroPeptide Sublingual Spray. Subsequent supplies will be payable on a yearly basis on the anniversary date of your first treatment.
The above costs do not include your travel to/from our clinics nor your accommodation and personal expenses. If you would like referrals on places to stay while visiting us for your treatment please let us know and we will be more than happy to assist you or click here for detailed information on travel directions to our clinics.
All treatment fees must be scheduled, booked, confirmed and paid in advance of your arrival in at any clinic.

IF YOU ARE INTERESTED IN PROGRESSING AND GETTING FURTHER INFORMATION CLICK HERE.

IF YOU WISH TO BOOK A CLINIC APPOINTMENT FOR TREATMENT AT A CLINIC NEAR YOU CLICK HERE.

IF YOU ARE INTERESTED IN VIEWING AVAILABLE CLINICS WORLDWIDE CLICK HERE.

FOR AN OVERVIEW OF THE ESPERANZA NEUROPEPTIDE TREATMENT PRICING CLICK HERE.

--------------------------------------------------------------------------------

What is Multiple Sclerosis?

Multiple Sclerosis (MS) is believed to be an autoimmune disease which primarily causes central nervous system problems. In MS, the insulating fatty material surrounding the nerve fibers, also known as myelin, which functions to speed signalling from one end of the nerve cell to another is attacked by cells of the immune system causing problems in signal transduction.

Multiple Sclerosis is the most common of demyelinating disorders, having a prevalence of approximately 1 per 1000 persons in most of the United States and Europe. A conservative estimate suggests 300,000 people in the US are affected with a global population of 3.0 million. Interestingly, cases of Multiple Sclerosis in the third world are uncommon.

Onset may occur at any age, but predominates in ages 20 to 40 years. An appearance of MS in childhood or after age 50 is relatively rare. Women are more often affected than men with an estimated ratio of 2 to 1 (DeGirolami et al., 1994). There is a silent, asymptomatic form of MS which is estimated to vary from 5% to 20% of all cases (Netter, 1986) and may be responsible for many cases going unreported.

The etiological agent for Multiple Sclerosis has not been identified but it is known that there are several contributing factors. Transmissible agents have been proposed in the pathogenesis of the disorder (HSV-6, EBV and retroviruses) but all attempts to identify a well-characterized virus has been unsuccessful. Some data suggests an environmental agent in the pathogenesis of this disease. Genetic influences are also clearly evident. The risk of developing MS is 15-fold higher when the disease is present in a first degree relative. One study in Israel indicated that persons immigrating there before their fifteenth year had the same liability for the disease as native Israelis, but those immigrating after fifteen years of age had the same propensity for the disease as people in their country of origin (Sheldon, 1992).

Our treatment:
Our sublingual NeuroPeptide for MS has shown great response in regards to the treatment of this disease and we are very encouraged by the feedback from patients having been treated to date. Please click here to see actual patient testimonials.

What is the prognosis?
There is no current cure for MS. The disorder is slowly progressive however, we have found that with our Peptide treatment for MS we are getting very promising responses and reversal of symptoms are prevalent in many cases. Our treatment is the only known treatment to document recovery of function in the body.

What research is being done?
We are constantly reviewing and updating our data on this disease and also looking into stem cell treatments in an attempt to find a path leading to a possible cure for MS. The Esperanza Research Foundation is funding this pioneering research in conjunction with Esperanza Peptide Ltd. and The International Centre Of Excellence Ltd.

How The Esperanza NeuroPeptide Works After Dosing:

Immediate results - I think it is important to note a few things in regards to "immediate results". First, the Esperanza NeuroPeptide was developed to combat MS, to cease new crises and to quell or lessen any future relapses and remissions developed pre Esperanza treatment. Function return is a BONUS ... and not specifically what the NeuroPeptide was developed to accomplish, nor is it the single indicator as to whether our NeuroPeptide treatment is working for our MS patients! Second ... Now the question asked is ... does function return appear in our patients ... Fortunately the answer is yes in many patients, and in some patients very early in their treatment, others show graduated response and some show much longer time frames. Although actual function return is a BONUS, I can say that across the board we do see almost immediate response in one or more areas of strength, balance, mobility, fine motor function, speech and/or cognitive function. An example of that is the last 12 patients tested showed improvement in strength and/or balance across the board at 15-150% positive difference post NeuroPeptide as opposed to pre NeuroPeptide on the same tests given prior to dosing and again tested an hour to an hour and a half post dosing. The significant areas of response are in the strength areas where (giving full effort from the patient both pre and post NeuroPeptide) the increase in strength in hands/arms was a positive in all 12 and ranging (as noted above from 15 - 150% increase). Balance was also significant, and in some cases going from inability to balance beyond 2-3 seconds before dosing and then going 2-3 minutes post dosing. Vibration testing also showed significant response and in one case a very distinct change in speech from a patient badly afflicted with speech problems due to MS. So, in reality ALL patients tested in the last 12 noted above have shown significant response in the tested areas and the numbers support that statement (and this is the general response that we get data feedback on). Of course, the main problem with MS and any other debilitating disease is the fact that patients in many cases are looking for an immediate and significant reversal of their disease and the symptoms pertaining thereto. Those treated recently range from 5 - 15 years diagnosed with MS and the disease has deteriorated their bodies over that extended period of time to different degrees and with different severity. So, function response to our NeuroPeptide and the degree and level of actual function response/benefit is very much an individual one. Remembering all of these patients are in their first few weeks of the NeuroPeptide treatment and as noted previously, ALL showed post NeuroPeptide increases in one or more of the tested areas.
Lets address later results - again I refer to the general principal of what our NeuroPeptide treatment was developed for and what it does within the body ... it was developed to combat MS, to cease new crises and to quell or lessen future relapses and remissions. Thus, the NeuroPeptide is always working in the system to combat the disease and to address the problems of connectivity in the body. You should look upon our NeuroPeptide for MS as diabetic patients look upon insulin for their disease. Our NeuroPeptide treatment is needed daily in the body to fight against the disease and as such we have a 26 hour sublingual protocol taken at the same time and same dosage each day to make sure that the system never runs out of the NeuroPeptide and the peptide is able to work fully in the body. Further, all bodies are different and I am sure you will agree that MS is different in individuals, thus if there is function return in patients, some may show immediate function return or improvement, some may show graduated response and some may show later response. There is no way at the moment to determine who or when or even if a person will get function return. However, many do and all are different in their responses and time frames. Suffice as to say, all are being protected within, which is what the NeuroPeptide was developed to do ... AGAIN and VERY IMPORTANT ... function return is a big and delightful BONUS that many are experiencing at different levels of their treatment time frame.
A question often asked is - "what percentage does it not work at all on"... again I have to revert back to the main function of the NeuroPeptide and the across the board results that show positive responses in all tested pre and post NeuroPeptide at one or more of the tested areas. Example, I have heard of a patient who stated recently that the NeuroPeptide is not working on him at all as he did not experience any immediate function return. Yet this very same patient scored 45 pounds pre peptide in a weak hand strength test to 75 pound post peptide with the same 100% effort ... this being 1 hour after peptide so there is a definite and amazing increase in strength to an MS afflicted weak side arm response there. The main problem is that this patient is looking to reverse his present situation of being in a wheelchair and unable to walk and would like to see that transpire immediately. Again,(and I cannot blame anyone for wanting to reverse the many years of damage that MS has delivered to any patients body) however, perception of what this patient sees as "working" as opposed to what the results show as significant response in output giving the same effort in the tests pre and post NeuroPeptide dosing is a matter of not taking into account what has been explained above as what the NeuroPeptide was developed to do as well as time frames pertaining to the treatment process being completely unique to each and every MS patient. Remembering again what the NeuroPeptide was developed to do as noted above and that function return is a BONUS that many are experiencing at various time frames in their treatment process!
Another question often asked ......"why does it work immediately on some and not on others". Again, a matter of perception ... if the test results show across the board increases post NeuroPeptide dosing, I would vigorously argue that it is working on all early on and doing exactly what it was developed to do! The difference of course is that some patients show remarkable (and in some cases almost immediate) return of function early on and yet some do not. Esperanza has always, and will always, analyse any and all treatments to try to determine as much about the treatment and responses that we can. We are constantly compiling data and reviewing cases and it is our hope to be able to determine why early and significant function return happens in some and not in others ... and hopefully those answers are forthcoming as part of our ongoing research campaign that has been ongoing now for over 23 years! I am delighted to say that we are indeed looking at one area that is showing very supportive data relating to those with the most debilitating symptoms from MS and what causes some to be more afflicted than others. This data is very interesting and will be compiled and published in the future.

Dosing Procedures And Protocol

Esperanza Homeopathic NeuroPeptide sublingual spray is self-administered by the patient (or carer) through a very unique and patent protected daily sublingual (under the tongue) spray delivery system ... see further details below:

The dosing procedure is very simple and is a unique once-a-day treatment.
The patient simply chooses a convenient time whereby (everyday at that same time) they would administer their daily dosage of Esperanza Homeopathic NeuroPeptide sublingual spray. It is important that this time is a convenient time daily so that the patient will easily get into a daily routine of taking the sublingual spray each and every day at the same time!
The dosing is done with 3 puffs (sprays) from our sublingual spray vials (under the tongue spray), then after waiting for 5 minutes another 3 puffs (sprays) are administered sublingually once again. The NeuroPeptide is thus absorbed into the body under the tongue (patient should not swallow the NeuroPeptide but should allow it to absorb into the body naturally and sublingually). This is the patient's entire dosage for the day. This is done each and every day at the same time each day to ensure 24 hour a day coverage and thus not having any drop-off of Esperanza Homeopathic NeuroPeptide coverage in the body. The 5 minute wait is to make sure the full dosage is received into the body daily as more than 3 puffs (sprays) at one time would be too much for the body to absorb sublingually and the patient would be inclined to swallow much of the NeuroPeptide and not getting the full dosing potential that is achieved with the 3 puffs (sprays) absorbed sublingually and then followed up 5 minutes later with another 3 puffs (sprays) absorbed sublingually. After dosing, the patient should not eat nor drink anything for at least 15 minutes to allow full absorption of the NeuroPeptide into the system.

The sublingual spray protocol noted above will cover the patient for an entire 24 hour period and offer the ultimate in Esperanza Homeopathic NeuroPeptide coverage in the body.

NOTE: the patient is required to take the Esperanza Homeopathic NeuroPeptide sublingual spray daily (similar to a diabetic taking insulin). Failure to keep up regular and timely dosing may result in a quick return of the MS symptoms as the sublingual spray stays in the body for up to a maximum of 26 hours and then wears off making effects of the NeuroPeptide on the symptoms cease rapidly thereafter. So, it is suggested that a convenient and dedicated time be established to administer each and every day!

For more information click here and/or to arrange a clinic booking please click here.

--------------------------------------------------------------------------------

What are Ataxias and Cerebellar/Spinocerebellar Degeneration?

Ataxia often occurs when parts of the nervous system that control movement are damaged. People with ataxia experience a failure of muscle control in their arms and legs, resulting in a lack of balance and coordination or a disturbance of gait. While the term ataxia is primarily used to describe this set of symptoms, it is sometimes also used to refer to a family of disorders. It is not, however, a specific diagnosis.

Most disorders that result in ataxia cause cells in the part of the brain called the cerebellum to degenerate, or atrophy. Sometimes the spine is also affected. The phrases cerebellar degeneration and spinocerebellar degeneration are used to describe changes that have taken place in a person's nervous system; neither term constitutes a specific diagnosis. Cerebellar and spinocerebellar degeneration have many different causes. The age of onset of the resulting ataxia varies depending on the underlying cause of the degeneration.

Many ataxias are hereditary and are classified by chromosomal location and pattern of inheritance: autosomal dominant, in which the affected person inherits a normal gene from one parent and a faulty gene from the other parent; and autosomal recessive, in which both parents pass on a copy of the faulty gene. Among the more common inherited ataxias are Friedreich's ataxia and Machado-Joseph disease. Sporadic ataxias can also occur in families with no prior history.

Ataxia can also be acquired. Conditions that can cause acquired ataxia include stroke, multiple sclerosis, tumors, alcoholism, peripheral neuropathy, metabolic disorders, and vitamin deficiencies.

Our treatment:
Our sublingual NeuroPeptide for ATAXIA has shown great response in regards to the treatment of this disease and we are very encouraged by the feedback from patients having been treated to date. Please click here to see actual patient testimonials.

What is the prognosis?
There is no current cure for ATAXIA. The disorder is slowly progressive however, we have found that with our Peptide treatment for ATAXIA we are getting very promising responses and reversal of symptoms are prevalent in many cases. Our treatment is the only known treatment to document recovery of function in the body.

What research is being done?
We are constantly reviewing and updating our data on this disease and also looking into stem cell treatments in an attempt to find a path leading to a possible cure for ATAXIA. The Esperanza Research Foundation is funding this pioneering research in conjunction with Esperanza Peptide Ltd. and The International Centre Of Excellence Ltd.

For more information click here and/or to arrange a clinic booking please click here.

--------------------------------------------------------------------------------

What is Stroke?

A stroke occurs when the blood supply to part of the brain is suddenly interrupted or when a blood vessel in the brain bursts, spilling blood into the spaces surrounding brain cells. Brain cells die when they no longer receive oxygen and nutrients from the blood or there is sudden bleeding into or around the brain. The symptoms of a stroke include sudden numbness or weakness, especially on one side of the body; sudden confusion or trouble speaking or understanding speech; sudden trouble seeing in one or both eyes; sudden trouble with walking, dizziness, or loss of balance or coordination; or sudden severe headache with no known cause. There are two forms of stroke: ischemic - blockage of a blood vessel supplying the brain, and hemorrhagic - bleeding into or around the brain.

Our treatment:
Our sublingual NeuroPeptide for STROKE has shown great response in regards to the treatment of this disease and we are very encouraged by the feedback from patients having been treated to date. Please click here.

What is the prognosis?
There is no current cure for POST STROKE conditions. However, we have found that with our Peptide treatment for STROKE we are getting very promising responses and reversal of symptoms are prevalent in many cases. Our treatment is the only known treatment to document recovery of function in the body.

What research is being done?
We are constantly reviewing and updating our data on this disease and also looking into stem cell treatments in an attempt to find a path leading to a possible cure for STROKE. The Esperanza Research Foundation is funding this pioneering research in conjunction with Esperanza Peptide Ltd. and The International Centre Of Excellence Ltd.

For more information click here and/or to arrange a clinic booking please click here.

--------------------------------------------------------------------------------

What is Primary Lateral Sclerosis?

Primary Lateral Sclerosis (PLS) is a rare neuromuscular disease characterized by progressive muscle weakness in the voluntary muscles. PLS belongs to a group of disorders known as motor neuron diseases. Motor neuron diseases develop when the nerve cells that control voluntary muscle movement degenerate and die, causing weakness in the muscles they control. Onset of PLS usually occurs after age 50. Symptoms may include difficulty with balance, weakness and stiffness in the legs, and clumsiness. Other symptoms may include spasticity (sudden, involuntary muscle spasms) in the hands, feet, or legs; foot dragging, and speech problems due to involvement of the facial muscles. The disorder usually begins in the legs, but it may also start in the tongue or the hands. The disease-which scientists believe is not hereditary-progresses gradually over a number of years, or even decades. In PLS, there is no evidence of the degeneration of spinal motor neurons or muscle wasting (amyotrophy) that occurs in amyotrophic lateral sclerosis or ALS (Lou Gehrig's disease), which it resembles. Diagnosis of PLS is often delayed because it is mistaken for ALS.

Our treatment:
Our sublingual NeuroPeptide for PLS has shown great response in regards to the treatment of this disease and we are very encouraged by the feedback from patients having been treated to date. Please click here.

What is the prognosis?
There is no current cure for PLS. The disorder is slowly progressive however, we have found that with our Peptide treatment for PLS we are getting very promising responses and reversal of symptoms are prevalent in many cases. Our treatment is the only known treatment to document recovery of function in the body.

What research is being done?
We are constantly reviewing and updating our data on this disease and also looking into stem cell treatments in an attempt to find a path leading to a possible cure for PLS. The Esperanza Research Foundation is funding this pioneering research in conjunction with Esperanza Peptide, Limited and The International Centre Of Excellence. Ltd.

For more information click here and/or to arrange a clinic booking please click here.

--------------------------------------------------------------------------------

What is Motor Neuron Disease/Amyotrophic Lateral Sclerosis (MND/ALS)?

Motor Neuron Disease/Amyotrophic Lateral Sclerosis (MND/ALS), (alternatively named Aran-Duchenne, Gehrig's Disease, Lou Gehrig's Disease), is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells (neurons) responsible for controlling voluntary muscles.

In MND/ALS, both the upper motor neurons and the lower motor neurons degenerate or die, ceasing to send messages to muscles. Unable to function, the muscles gradually weaken, waste away, and twitch. Eventually the ability of the brain to start and control voluntary movement is lost.

Individuals with MND/ALS lose their strength and the ability to move their arms, legs, and body. When muscles in the diaphragm and chest wall fail, individuals lose the ability to breathe without ventilatory support. The disease does not affect a person's ability to see, smell, taste, hear, or recognize touch, and it does not usually impair a person's thinking or other cognitive abilities. However, several recent studies suggest that a small percentage of patients may experience problems with memory or decision-making, and there is growing evidence that some may even develop a form of dementia.

The cause of ALS is not known, and scientists do not yet know why ALS strikes some people and not others.

There is no one test or procedure to establish the diagnosis of ALS. The diagnosis of ALS is based on history, neurological findings consistent with the diagnosis of ALS and eletrophysiological and neuroimaging testing to rule out other impairments that may cause similar signs and symptoms. The diagnosis may be supported by electrophysiological studies (electromyogram [EMG] and nerve conduction study [NCS] but these tests may be negative or only suggestive of the diagnosis.

No cure to date has been found for ALS and treatment based around controlling progression of the disease is paramount.

Regardless of the part of the body first affected by the disease, muscle weakness and atrophy spread to other parts of the body as the disease progresses. Most individuals with ALS are inflicted with serious respiratory failure, usually within 3 to 5 years from the onset of symptoms.

Our treatment:
Our sublingual NeuroPeptide for MND/ALS has shown great response in regards to the treatment of this disease and we are very encouraged by the feedback from patients having been treated to date. Please click here to see actual patient testimonials.

What is the prognosis?
There is no current cure for MND/ALS. The disorder is rapidly progressive however, we have found that with our NeuroPeptide treatment for MND/ALS we are getting very promising responses in many cases.

What research is being done?
We are constantly reviewing and updating our data on this disease and also looking into stem cell treatments in an attempt to find a path leading to a possible cure for MND/ALS. The Esperanza Research Foundation is funding this pioneering research in conjunction with Esperanza Peptide Ltd.

For more information click here and/or to arrange a clinic booking please click here.

--------------------------------------------------------------------------------

What are Neurological Complications Of Lyme Disease?

Lyme disease (LYME) is caused by a bacterial organism that is transmitted to humans via the bite of an infected tick. Most people bitten by an infected tick develop a characteristic skin rash around the area of the bite. The rash may feel hot to the touch, and vary in size, shape, and color, but it will often have a "bull's eye" appearance (a red ring with a clear center). However, there are those who will not develop the rash, which makes Lyme disease hard to diagnose because its symptoms and signs mimic those of many other diseases.

Seven to 10 days following an infected tick's bite, the first stage of Lyme disease begins with flu-like symptoms such as fever, chills, swollen lymph nodes, headaches, fatigue, muscle aches, and joint pain.

Neurological complications most often occur in the second stage of Lyme disease, with numbness, pain, weakness, Bell's palsy (paralysis of the facial muscles), visual disturbances, and meningitis symptoms such as fever, stiff neck, and severe headache. Other problems, which may not appear until weeks, months, or years after a tick bite, include decreased concentration, irritability, memory and sleep disorders, and nerve damage in the arms and legs.

Our treatment:
Our sublingual Peptide for LYME has shown great response in regards to the treatment of this disease and we are very encouraged by the feedback from patients having been treated to date. Our protocol for Lyme disease treatment is antibiotics for a minimum of 12 weeks (or for as long as necessary to kill off the spirochetes in the body) and our Peptide for at least one year. Ongoing testing is required to check on the Lyme/Spirochete presence in the body. Please click here to see actual patient testimonials.

What is the prognosis?
Most individuals with Lyme disease respond well to antibiotics and have full recovery. In a few patients symptoms of persisting infection may continue or recur, requiring additional antibiotic treatment. Our protocol for Lyme disease treatment is antibiotics for a minimum of 12 weeks (or for as long as necessary to kill off the spirochetes in the body) and our Peptide for at least one year. There is every chance that if you have Lyme you can be fully treated so as to eliminate Lyme Diseases (and spirochetes) from your system. Our treatment is the only known treatment to document recovery of function in the body.

What research is being done?
We are constantly reviewing and updating our data on this disease and also looking into more advanced diagnostic testing. The Esperanza Research Foundation is funding this pioneering research in conjunction with Esperanza Peptide Ltd. and The International Centre Of Excellence Ltd.

For more information click here and/or to arrange a clinic booking please click here.